Clinical Trial Detail

NCT ID NCT02781506
Title Nivolumab and Stereotactic Ablative Radiation Therapy Versus Nivolumab Alone for Metastatic Renal Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Texas Southwestern Medical Center
Indications

renal cell carcinoma

Therapies

Nivolumab

Age Groups: adult senior

No variant requirements are available.